Vividion Therapeutics, Inc.
Clinical trials sponsored by Vividion Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat cancers in early trial Results expected May 2027 (estimated)
- New cancer drug combo enters first human tests Results expected Aug 2027 (estimated)
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…
Phase 1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can blocking a DNA repair protein make immunotherapy work better against colorectal cancer?
Disease control Recruiting nowResearchers are testing a new drug, VVD-133214, combined with pembrolizumab in people with advanced colorectal cancer that has MSI and/or dMMR. These tumors rely on a protein called Werner helicase to survive, and VVD-133214 is designed to block it. The trial compares the combina…
Phase 2 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug hopes to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…
Phase 1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cancer drug combo enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…
Phase 1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC